NICE recommends PONVORY for the treatment of relapsing forms of multiple sclerosis

NICE has issued a positive Final Appraisal Document (FAD) recommending PONVORY® (ponesimod) as an option in England and Wales for the treatment of relapsing-remitting multiple sclerosis (RRMS). The once-daily oral treatment has been approved for adults with active disease defined by clinical or imaging features. RRMS is the most common form of MS, where attackes (relapses) are followed by periods of partial or complete recovery.

read more